Why Johnson & Johnson Stock Dropped Today
Key Points
Johnson & Johnson beat "adjusted earnings" estimates.
Its actual GAAP profits plummeted 96%.
- Motley Fool Issues Rare "Total Conviction" Buy Alert ›
Johnson & Johnson (NYSE:JNJ) stock tumbled 6.8% through 12:30 p.m. ET Tuesday despite delivering an earnings beat this morning and raising guidance for the rest of 2026.
Heading into earnings day, analysts expected Johnson & Johnson to earn $2.53 in "adjusted" earnings on $25.4 billion in sales for Q3. In fact, J&J says it earned $2.59 per share, adjusted, and beat slightly on sales as well.
Missed AI’s "Act 1"? Act 2 Could Be 15x Bigger. Most investors think they missed the AI boat because they didn't buy Nvidia in 2005. But according to our analysts, we’re only at the end of "Act 1"—the R&D phase. "Act 2" is the global rollout. Continue »
Image source: Johnson & Johnson.
Johnson & Johnson Q3 earnings
Johnson & Johnson grew its sales 5.9% in Q3, but despite beating on earnings, its adjusted profit was down 7.5% -- and its GAAP profit was down much, much more. Blaming a "one-time special charge for the proposed talc litigation resolution, the acquisition of Firefly Bio, Inc., and the strategic collaboration with Sail Biomedicines" for the news, J&J admitted that its Q3 earnings calculated under generally accepted accounting principles (GAAP) came to just $0.09 per share.
That's a 96% year-over-year decline.
What's next for Johnson & Johnson
So you can see why investors were just a wee bit upset with the news. But should they be?
Yes, earnings were down dramatically, but on the plus side, free cash flow increased more than 6% to $15.1 billion. What's more, the declines were expected, and ended up being less bad than feared. On top of all that, J&J raised its guidance for the rest of this year. Management now anticipates that 2026 sales will grow 7.4% to $101.2 billion, and its adjusted earnings could be $11.10 per share.
My problem with all this, though, is that... it's not enough.
Valued even on adjusted earnings, Johnson & Johnson stock costs more than 22x earnings. Valued on free cash flow, the multiple is closer to 29x. I just don't see how 7%-ish growth is good enough to support that.
To me, Johnson & Johnson stock looks like a sell.
Should you buy stock in Johnson & Johnson right now?
Before you buy stock in Johnson & Johnson, consider this:
The Motley Fool Stock Advisor analyst team just identified what they believe are the 10 best stocks for investors to buy now… and Johnson & Johnson wasn’t one of them. The 10 stocks that made the cut could produce monster returns in the coming years.
Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you’d have $380,795!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you’d have $1,390,634!*
Now, it’s worth noting Stock Advisor’s total average return is 946% — a market-crushing outperformance compared to 215% for the S&P 500. Don't miss the latest top 10 list, available with Stock Advisor, and join an investing community built by individual investors for individual investors.
See the 10 stocks »
*Stock Advisor returns as of October 13, 2026.
Rich Smith has no position in any of the stocks mentioned. The Motley Fool recommends Johnson & Johnson. The Motley Fool has a disclosure policy.
Recommended Articles
